| Filed | Form | Items | Signal | Score | Summary | Link |
|---|---|---|---|---|---|---|
| 2026-06-09 17:04 | 8-K | ["8.01", "9.01"] | other | 0.05 | Clinical program milestone announcement with no M&A relevance. | SEC · detail |
| 2026-05-19 16:30 | 8-K | ["5.02", "7.01", "9.01"] | officer change | 0.15 | Appointment of Chief Medical Officer with standard compensation package; no M&A indicators present. | SEC · detail |
| 2026-05-12 07:44 | 8-K | ["8.01", "9.01"] | other | 0.05 | 8-K announces positive clinical trial data for fasedienol; no M&A signals present. | SEC · detail |
| 2026-05-08 16:30 | 8-K | ["8.01", "9.01"] | other | 0.05 | Clinical trial completion announcement; no M&A, activist, or strategic transaction signals present. | SEC · detail |
| 2026-04-28 16:13 | 8-K | ["8.01", "9.01"] | other | 0.05 | FDA approval letter for clinical trial progression; no M&A indicators present. | SEC · detail |